Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab)...
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
April 17, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the...
More Than 3.6 Million Births Recorded in the United States in 2024, Up 1 Percent From 2023
In 2024, the provisional number of births in the United States was 3,622,673, which was 1 percent higher than in 2023, according to an April Vital Statistics...
Patients Mainly Prefer AI as Second Reader for Screening Mammogram
Use of artificial intelligence (AI) as a second reader in screening mammography is accepted by patients, according to a study published online April 18...
FDA Approves Dupixent for Chronic Spontaneous Urticaria
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.The...
Study IDs Predictors of Biomechanical Function in Patients With OA Undergoing Hip Replacement
For patients undergoing total hip arthroplasty (THA), osteoarthritis (OA) severity is the best predictor of preoperative biomechanical function, and preoperative...
Maternal Anemia in Early Pregnancy May Increase Risk for Congenital Heart Disease
Maternal anemia in early pregnancy is associated with an increased risk for congenital heart disease (CHD) in offspring, according to a study published...
Some OB/GYNS Stay in States With Abortion Bans, Despite Legal Risks
WEDNESDAY, April 23, 2025 — Three years after the U.S. Supreme Court ended the federal right to abortion, doctors who specialize in obstetrics and...
Teen Cannabis Use Rises in Canada After Edibles Are Legalized
WEDNESDAY, April 23, 2025 — Teen cannabis use rose significantly in parts of Canada after edibles were legalized, a new study shows. The study found...
Federal Prosecutor Questions Medical Journals Over Alleged Bias
WEDNESDAY, April 23, 2025 — At least three medical journals have received letters from a top federal prosecutor questioning whether they mislead...
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
(BUSINESS WIRE) Apr 22, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy...
FDA Alerts Health Care Providers, Compounders and Consumers of Potential Risks Associated with Compounded Topical Finasteride Products
FDA has become aware of reports of adverse events involving compounded topical finasteride products potentially putting consumers at risk. The agency is...
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter
Bridgewater, NJ, Amneal Pharmaceutical LLC, is recalling two lots of Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, Infusion bags to the hospital/user...
Common Meds Appear To Delay Onset Of Parkinson's Disease
Common medications like aspirin, ibuprofen, statins and beta blockers appear to slow the progress of Parkinson’s disease, a new study says. Parkinson’s...
Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared...
Recently Added
Recently added consumer and prescribing information: Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten, Aucatzyl
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Jobevne Jobevne (bevacizumab-nwgd) is a vascular endothelial growth factor inhibitor biosimilar to Avastin used for the treatment of colorectal...
- Vanrafia Vanrafia (atrasentan) is an endothelin A receptor antagonist used for proteinuria reduction in primary immunoglobulin (IgA) nephropathy.
- Qfitlia Qfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid for the prophylactic treatment of people with hemophilia...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...